SMSusan Lynne McGovern

Susan Lynne McGovern

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan Lynne McGovern has a total of 220 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology Committees

    by Hesham Elhalawani, Rachel K. Peterson, Avani D. Rao, Laurie J. McKenzie, Ahmed Magdy Elmotayam, Leslie Chang, Michael Roth, Susan L. McGovern

    Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges. Overall, these result in worse outcomes for AYAs compared to older and younger patients. The physical, mental, social, and holistic impacts of radiation in this population are only beginning to be understood. This review will summarize the current state of knowledge of the impacts of radiation on AYAs and highlight opportunities for future investigation.

  • Open Access

    Supplementary Table S2 from Dose Escalation with Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas – Results from a Phase I Trial

    by Felix Ehret, Nora K. Horick, Beow Y. Yeap, William T. Curry, Brian Nahed, Juliane Daartz, Jason M. Johnson, Samir A. Dagher, Shaan M. Raza, Franco DeMonte, et al.

    Study Representativeness Table.

  • Open Access

    Supplementary Data S1 from Dose Escalation with Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas – Results from a Phase I Trial

    by Felix Ehret, Nora K. Horick, Beow Y. Yeap, William T. Curry, Brian Nahed, Juliane Daartz, Jason M. Johnson, Samir A. Dagher, Shaan M. Raza, Franco DeMonte, et al.

    Organs at risk dose constraints.

  • Open Access

    Data from Dose Escalation with Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas – Results from a Phase I Trial

    by Felix Ehret, Nora K. Horick, Beow Y. Yeap, William T. Curry, Brian Nahed, Juliane Daartz, Jason M. Johnson, Samir A. Dagher, Shaan M. Raza, Franco DeMonte, et al.

    Purpose:Outcomes for grade 2 and 3 meningiomas are poor. A few studies suggest a benefit from radiotherapy dose escalation. This trial evaluates the safety and efficacy of dose escalation with intensity-modulated proton therapy (IMPT) for grade 2 and 3 meningiomas. Patients and Methods:This prospective single-arm phase I trial enrolled patients with grade 2 meningioma with residual disease or recurrence or patients with grade 3 meningioma after gross total resection. Patients underwent dose-escalated IMPT to 66 Gy relative biological effectiveness [Gy(RBE)] for grade 2 gross disease and 63 Gy(RBE) for grade 3 tumor beds. The primary endpoint was acute dose-limiting toxicity (DLT). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and late toxicity. Results:Twenty-one patients with 16 grade 2 and 5 grade 3 meningiomas were enrolled and treated between 2016 and 2023. The median clinical and radiographic follow-up periods were 3.4 and 3.2 years, respectively. No DLT was observed. Five new late grade 3 toxicities occurred in four patients. Three treatment failures were observed in two grade 2 and one grade 3 tumors. Two deaths occurred in patients with grade 2 meningiomas. The 1-, 2-, and 3-year PFS rates were 100%, 95%, and 88.2%, respectively. The corresponding OS rates were 100%, 95%, and 95%, respectively. Conclusions:This first prospective trial investigating dose-escalated IMPT for high-grade meningiomas demonstrated a favorable early safety profile and clinical outcomes. Phase II and III studies are warranted to confirm the superiority of dose escalation for high-grade meningiomas.

  • Open Access

    Supplementary Figure S1 from Dose Escalation with Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas – Results from a Phase I Trial

    by Felix Ehret, Nora K. Horick, Beow Y. Yeap, William T. Curry, Brian Nahed, Juliane Daartz, Jason M. Johnson, Samir A. Dagher, Shaan M. Raza, Franco DeMonte, et al.

    Overall survival. A: Complete cohort. B: Stratified by WHO grading. C: Stratified by treatment indication.

  • Open Access

    Supplementary Table S1 from Dose Escalation with Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas – Results from a Phase I Trial

    by Felix Ehret, Nora K. Horick, Beow Y. Yeap, William T. Curry, Brian Nahed, Juliane Daartz, Jason M. Johnson, Samir A. Dagher, Shaan M. Raza, Franco DeMonte, et al.

    Local failure rates, progression-free survival, and overall survival.

  • Open Access

    Clinical and Molecular Features of BAP1‐Mutated Meningiomas: Case Series

    by Ivan Pradilla, Rasha Alfattal, Susan L. McGovern, Shaan M. Raza, Franco DeMonte, Leomar Y. Ballester, Chirag B. Patel, Carlos Kamiya‐Matsuoka

    BRCA1‐associated protein 1 (BAP1)‐deficient meningiomas represent a clinically and molecularly distinct subgroup with variable histology and aggressive behavior that may not be fully captured by current grading criteria. The clinical spectrum of BAP1 alterations in meningiomas, including both somatic and germline contexts, remains incompletely characterized. We report three cases of BAP1‐deficient meningiomas with divergent clinical trajectories. Case 1 was a 44‐year‐old woman with a somatic BAP1 nonsense mutation (Q392*) presenting as recurrent spinal meningiomatosis. Despite WHO grade 1 histology with rhabdoid features and no high‐grade criteria, she experienced rapid recurrence and required multiple resections, radiation, and systemic therapy, illustrating that truncating somatic mutations may drive aggressive behavior independent of histological grade. Case 2 was a 22‐year‐old man harboring a germline BAP1 truncating mutation (R385*) with a family history of meningioma, who presented with a WHO grade 3 papillary meningioma and remained progression‐free 24 months after resection and adjuvant radiotherapy. His family pedigree represents a rare phenotype within the BAP1 tumor predisposition syndrome. Case 3 was a 57‐year‐old man with a low‐variant‐allele‐frequency BAP1 missense mutation (Y173C) and WHO grade 2 meningioma who demonstrated a favorable course at 26 months following gross total resection without adjuvant therapy. These cases illustrate the phenotypic heterogeneity of BAP1‐deficient meningiomas and underscore that truncating mutations, particularly somatic ones, may confer aggressive behavior regardless of histological grade. Variant allele frequency and mutation type should inform risk stratification alongside traditional pathological features. Consideration of BAP1 as a defining molecular feature in future WHO classification iterations is likely warranted.

  • Dose Escalation With Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas – Results From a Phase 1 Trial

    by Felix Ehret, Nora K. Horick, Beow Y. Yeap, William T. Curry, Brian Nahed, Juliane Daartz, Jason M. Johnson, Samir A. Dagher, Shaan M. Raza, Franco DeMonte, et al.

    Background: Outcomes for grade 2 and 3 meningiomas are poor. A few studies suggest a benefit from radiation therapy dose escalation. This trial evaluates the safety and efficacy of dose escalation with intensity-modulated proton therapy (IMPT) for grade 2 and 3 meningiomas. Methods: This prospective single-arm phase 1 trial enrolled patients with grade 2 meningioma with residual disease or recurrence, or patients with grade 3 meningioma after gross total resection. Patients underwent dose-escalated IMPT to 66 Gy (relative biological effectiveness, RBE) for grade 2 gross disease and 63 Gy(RBE) for grade 3 tumor beds. The primary endpoint was acute dose-limiting toxicity (DLT). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and late toxicity. Results: Twenty-one patients with 16 grade 2 and five grade 3 meningiomas were enrolled and treated between 2016 and 2023. The median clinical and radiographic follow-up periods were 3.4 and 3.2 years, respectively. No DLT was observed. Five new late grade 3 toxicities occurred in four patients. Three treatment failures were observed in two grade 2 and one grade 3 tumors. Two deaths occurred in patients with grade 2 meningiomas. The 1-, 2-, and 3-year PFS rates were 100%, 95.0%, and 88.2%, respectively. The corresponding OS rates were 100%, 95.0%, and 95.0%, respectively. Conclusions: This first prospective trial investigating dose-escalated IMPT for high-grade meningiomas demonstrated a favorable early safety profile and clinical outcomes. Phase 2 and 3 studies are warranted to confirm the superiority of dose escalation for high-grade meningiomas.

  • Clinical Applications of Particle Therapy in Pediatric Malignancies

    by Madeline M. Flanagan, Ory Haisraely, Arnold C. Paulino, Susan L. McGovern

    In children, decades of survivorship magnify the harms of irradiation to normal tissues. Proton therapy (PT) leverages the Bragg peak phenomenon to maintain dose to tumor volumes while reducing dose to surrounding structures. This results in disease control comparable to photons while lowering normal tissue dose and reducing subsequent late effects. The clearest advantages occur when fields are large or when critical organs abut the target volume. Here, we discuss the clinical physics and comparative dosimetry that drive benefit across pediatric indications. We also synthesize PT outcomes for pediatric malignancies and highlight organ-specific late effects where PT reduces the incidence or severity of toxicities. We close with a brief look at the future of particle therapy for pediatric malignancies.

  • Open Access

    Long-term Musculoskeletal and Marrow Sparing with Proton FLASH in Juvenile Mice: Implications for Pediatric Osteosarcoma

    by Zongsheng Hu, Uwe Titt, Yuting Li, Elise Konradsson, Edgardo A Aguilar, Denae W Neill, Luke Connell, Xiaochun Wang, Henry James Meyer, Mihai Lurascu Gagea, et al.

    Purpose: Osteosarcoma is the most common primary bone malignancy in children and adolescents. Radiotherapy is limited by intrinsic radioresistance and the risk of severe long-term musculoskeletal toxicities. FLASH radiotherapy, delivered at ultra-high dose rates (>40 Gy/s), has demonstrated normal tissue sparing in preclinical models, but its effects on the developing skeleton and marrow remain poorly defined. This study evaluated the chronic normal tissue effects of proton FLASH in juvenile mice, modeling the pediatric context. Methods and Materials: Juvenile C57BL/6 mice (3–4 weeks old) were randomized to receive 11 Gy FLASH (≈200 Gy/s) or conventional proton irradiation (0.2 Gy/s average), or sham treatment to the left hind leg using a synchrotron-based proton beamline. Mice were followed for 10 weeks post-treatment. Bone toxicity was assessed with microCT (bone mineral density, bone volume fractions, trabecular indices) and histology. Bone marrow cellularity was quantified on H&E-stained sections, and muscle fibrosis was assessed using Masson’s trichrome. Results: FLASH-treated mice exhibited significant preservation of bone microarchitecture compared with conventional treated mice, with higher bone mineral density and bone volume fractions (p < 0.05). Trabecular numbers were maintained, while structure model index indicates a mechanically favorable trabecular structures in the FLASH group. Bone marrow cellularity was preserved in FLASH mice (5.3% reduction vs. sham) compared with conventional (11.3 % reduction, p < 0.05). Muscle fibrosis was significantly lower in FLASH group (fibrosis positivity 2.6 % vs. 3.0% for FLASH vs. conventional CONV, p < 0.05). No severe immobility or weight loss was observed across groups. Conclusions: Proton FLASH significantly reduces long-term bone, marrow, and muscle toxicities in juvenile mice. These findings provide the first demonstration of musculoskeletal sparing in a synchrotron proton FLASH platform and highlight its translational potential for pediatric osteosarcoma.